

Eileen O Dareng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7565055/publications.pdf>

Version: 2024-02-01

47
papers

829
citations

623734

14
h-index

526287

27
g-index

51
all docs

51
docs citations

51
times ranked

1454
citing authors

#	ARTICLE	IF	CITATIONS
1	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. <i>European Journal of Human Genetics</i> , 2022, 30, 349-362.	2.8	23
2	chromMAGMA: regulatory element-centric interrogation of risk variants. <i>Life Science Alliance</i> , 2022, 5, e202201446.	2.8	1
3	Ovarian Cancer Risk Variants Are Enriched in Histotype-Specific Enhancers and Disrupt Transcription Factor Binding Sites. <i>American Journal of Human Genetics</i> , 2020, 107, 622-635.	6.2	14
4	High-depth African genomes inform human migration and health. <i>Nature</i> , 2020, 586, 741-748.	27.8	197
5	Vaginal microbiota diversity and paucity of <i>Lactobacillus</i> species are associated with persistent hrHPV infection in HIV negative but not in HIV positive women. <i>Scientific Reports</i> , 2020, 10, 19095.	3.3	14
6	Prevalence and incidence of genital warts and cervical Human Papillomavirus infections in Nigerian women. <i>BMC Infectious Diseases</i> , 2019, 19, 27.	2.9	20
7	PE-1 Vaginal microbiota composition and persistent high-risk HPV infection in HIV negative and HIV positive women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 65-65.	2.1	0
8	Implementation of genomics research in Africa: challenges and recommendations. <i>Global Health Action</i> , 2018, 11, 1419033.	1.9	36
9	Clearance of Type-Specific, Low-Risk, and High-Risk Cervical Human Papillomavirus Infections in HIV-Negative and HIV-Positive Women. <i>Journal of Global Oncology</i> , 2018, 4, JCO.17.00129.	0.5	12
10	Secular trend in interobserver agreement of VIA diagnosis for cervical cancer screening in Nigeria. <i>PLoS ONE</i> , 2018, 13, e0208531.	2.5	3
11	Age, HIV status, and research context determined attrition in a longitudinal cohort in Nigeria. <i>Journal of Clinical Epidemiology</i> , 2018, 100, 32-43.	5.0	7
12	Cohort Profile: African Collaborative Center for Microbiome and Genomics Research's (ACCME's) Human Papillomavirus (HPV) and Cervical Cancer Study. <i>International Journal of Epidemiology</i> , 2017, 46, 1745-1745j.	1.9	30
13	Incidence, Persistence, and Determinants of Human Papillomavirus: A Prospective Cohort Study of HIV-Negative Nigerian Women. <i>Journal of Global Oncology</i> , 2017, 3, 39s-40s.	0.5	1
14	Persistent Low-Risk and High-Risk Human Papillomavirus Infections of the Uterine Cervix in HIV-Negative and HIV-Positive Women. <i>Frontiers in Public Health</i> , 2017, 5, 178.	2.7	37
15	Attitude to Human Papillomavirus Deoxyribonucleic Acid-Based Cervical Cancer Screening in Antenatal Care in Nigeria: A Qualitative Study. <i>Frontiers in Public Health</i> , 2017, 5, 226.	2.7	9
16	Test-Retest Reliability of Self-Reported Sexual Behavior History in Urbanized Nigerian Women. <i>Frontiers in Public Health</i> , 2017, 5, 172.	2.7	10
17	Cancers Attributable to Alcohol Consumption in Nigeria: 2012-2014. <i>Frontiers in Oncology</i> , 2017, 7, 183.	2.8	9
18	Incidence, persistence and determinants of human papillomavirus: A prospective cohort study of 10,000 HIV-negative Nigerian women.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1510-1510.	1.6	0

#	ARTICLE	IF	CITATIONS
19	Reliability of Self Reported Sexual Behaviour History. <i>Journal of Global Oncology</i> , 2016, 2, 79s-79s.	0.5	0
20	Burden of Cancers Attributable to Infectious Agents in Nigeria: 2012â€“2014. <i>Frontiers in Oncology</i> , 2016, 6, 216.	2.8	18
21	Risk, Persistence and Multiplicity of HPV Infections among HIV Negative and HIV Positive Nigerian Women. <i>Journal of Global Oncology</i> , 2016, 2, 38s-39s.	0.5	0
22	P-B25â€fInfluence of spirituality and modesty on acceptance of self sampling for cervical cancer screening. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 84.	2.1	1
23	P-B29â€fBarriers to cervical cancer screening among Nigerian women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 86.	2.1	1
24	P-B31â€fCohort profile. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 87.	2.1	18
25	P-B17â€fPersistent human papillomavirus infection in a cohort of Nigerian women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 80.	2.1	0
26	P-B16â€fThe Burden of human papilloma virus associated cancers in Nigeria 2012â€“2014. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 79.	2.1	0
27	P-B30â€fAssociation between HIV and persistent HPV infections among Nigerian women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 86.	2.1	0
28	P-B24â€fFactors associated with attrition in a prospective cohort study in Nigeria. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 83.	2.1	0
29	Prevalent high-risk HPV infection and vaginal microbiota in Nigerian women. <i>Epidemiology and Infection</i> , 2016, 144, 123-137.	2.1	104
30	P-B22â€fRecurrence of cervical intraepithelial lesions after Thermo-coagulation in HIV-positive and HIV-negative Nigerian Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 82.	2.1	0
31	The burden of HPV associated cancers in two regions in Nigeria 2012â€“2014. <i>Cancer Epidemiology</i> , 2016, 45, 91-97.	1.9	13
32	Qualitative study of barriers to cervical cancer screening among Nigerian women. <i>BMJ Open</i> , 2016, 6, e008533.	1.9	82
33	Recurrence of cervical intraepithelial lesions after thermo-coagulation in HIV-positive and HIV-negative Nigerian women. <i>BMC Women's Health</i> , 2016, 16, 25.	2.0	24
34	P-B12â€fComparison of HPV genotyping using roche linear array with Spf10-Deia Lipa 25 Version 1 in Nigerian women presenting for cervical cancer screening. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 77.	2.1	0
35	P-B20â€fEvaluation of the feasibility of incorporating HPV DNA- based cervical cancer screening into routine antenatal care in Nigeria. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 81.	2.1	0
36	P-B33â€fHPV Persistence and age-specific type distribution among Nigerian women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 88.	2.1	0

#	ARTICLE	IF	CITATIONS
37	Cohort profile: African Collaborative Center for Microbiome and Genomics Research (ACCME) study.. Journal of Clinical Oncology, 2016, 34, 5524-5524.	1.6	1
38	Incidence, clearance and predictors of type-specific HPV infection among Nigerian women.. Journal of Clinical Oncology, 2016, 34, e17001-e17001.	1.6	1
39	Risk, persistence, and multiplicity of HPV infections among HIV-negative and HIV-positive Nigerian women.. Journal of Clinical Oncology, 2016, 34, 1565-1565.	1.6	0
40	Influence of Spirituality and Modesty on Acceptance of Self-Sampling for Cervical Cancer Screening. PLoS ONE, 2015, 10, e0141679.	2.5	20
41	P-A4â€fPrevalence and Incidence of genital warts among women in Nigeria. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 67, 77.	2.1	0
42	Age-specific prevalence of human papilloma virus infection among Nigerian women. BMC Public Health, 2014, 14, 656.	2.9	50
43	P-C2â€fPersistence of high risk Human Papillomavirus infection among Nigerian women. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 67, 84.	2.1	0
44	HIV associated high-risk HPV infection among Nigerian women. BMC Infectious Diseases, 2013, 13, 521.	2.9	44
45	RPS19 and TYMS SNPs and Prevalent High Risk Human Papilloma Virus Infection in Nigerian Women. PLoS ONE, 2013, 8, e66930.	2.5	17
46	Abstract 2588: Increased risk of prevalent high risk human papillomavirus infection in <i>Lactobacillus iners</i> rich microbiota in Nigerian women.. Cancer Research, 2013, 73, 2588-2588.	0.9	1
47	HIV-associated high-risk HPV infection in Nigerian women.. Journal of Clinical Oncology, 2013, 31, 1576-1576.	1.6	3